Lei Shi
Senior Partner and Co-Head of Eight Roads Ventures China Healthcare
Lei Shi is a Senior Partner and Co-Head of the China healthcare franchise. Lei has led investments in companies like Nanos Medical, RedPine, EurekaBio, ingeDx, Precision Robotics and SonoSemi and generated strong returns from companies such as Cytek Biosciences (NASDAQ: CTKB) and MDDF.

What motivates you?

Believing in technology as the fundamental driver to improve our society’s well-being, I’m thrilled by the opportunity to work with some of Asia's most talented entrepreneurs, promoting the advancement of technology and its adoption in successful enterprises.

What’s been the steepest learning curve on your career journey so far?

My first few projects at McKinsey transformed me from a nerdy Ph.D. to someone who realised the power of business. That experience shaped my career and my commitment to make an impact by combining genuine technological advancement and smart business models.

Which global technology trend are you most excited about at the moment and why?

New healthcare models enabled by the digitalisation of medical data: real-time data acquisition and analytics about the human body and our environment will transform healthcare practices as we know it.

What’s the best piece of advice you’ve ever received?

“Abundance - The future is better than you think”, so pursue whatever you’re truly passionate about and build your edge.

What is the company you wish you’d backed and why?

SpaceX – as important as its multi-planetary vision has been its ability to build an enthusiastic team and choose the right business model, the right timing and the right technology to shake the established (or stand-still) aerospace industry. Fortunately for start-ups today, there are similar abundant opportunities in the fertile ground of many established industries.

The information on these pages is intended solely for the benefit of entrepreneurs and businesses seeking venture capital investment. Eight Roads does not offer and is not offering to provide investment advisory services nor is it offering to engage in any transactions in securities.